Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States
Traditional influenza vaccines may be less immunogenic in adults ≥65 years of age due to immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose influenza vaccine (HD-IIV3)—were developed to overcome this problem. We summarize estimates...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/9/1456 |
| _version_ | 1797481609398583296 |
|---|---|
| author | Constantina Boikos Ian McGovern Justin R. Ortiz Joan Puig-Barberà Eve Versage Mendel Haag |
| author_facet | Constantina Boikos Ian McGovern Justin R. Ortiz Joan Puig-Barberà Eve Versage Mendel Haag |
| author_sort | Constantina Boikos |
| collection | DOAJ |
| description | Traditional influenza vaccines may be less immunogenic in adults ≥65 years of age due to immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose influenza vaccine (HD-IIV3)—were developed to overcome this problem. We summarize estimates of the relative vaccine effectiveness (rVE) of aIIV3 vs. HD-IIV3 and aIIV3 vs. standard, egg-based quadrivalent influenza vaccines (IIV4e) during the 2017–2018, 2018–2019, and 2019–2020 US influenza seasons using the same underlying electronic medical record and linked claims dataset for all three seasons. The primary outcome was influenza-related medical encounters (IRMEs), defined by diagnostic codes specific to influenza (ICD J09*-J11*). rVE was estimated using propensity score methods adjusting for demographics and health status. rVE estimates demonstrated consistent benefit for aIIV3 over IIV4e in the overall and at-risk populations. Relative to HD-IIV3, aIIV3 provided improved benefit in the overall study population and comparable benefit in the at-risk population across each season. |
| first_indexed | 2024-03-09T22:17:02Z |
| format | Article |
| id | doaj.art-2b74e9a65d594cbb8bd95b40ec903a00 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:17:02Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2b74e9a65d594cbb8bd95b40ec903a002023-11-23T19:21:25ZengMDPI AGVaccines2076-393X2022-09-01109145610.3390/vaccines10091456Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United StatesConstantina Boikos0Ian McGovern1Justin R. Ortiz2Joan Puig-Barberà3Eve Versage4Mendel Haag5Seqirus Inc., Kirkland, QC H9H 4M7, CanadaSeqirus USA, Cambridge, MA 02139, USACenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USAFoundation for the Promotion of Health and Biomedical Research (FISABIO), 46020 Valencia, SpainSeqirus USA, Cambridge, MA 02139, USASeqirus Inc., 1101 CL Amsterdam, The NetherlandsTraditional influenza vaccines may be less immunogenic in adults ≥65 years of age due to immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated influenza vaccine (aIIV3) and high-dose influenza vaccine (HD-IIV3)—were developed to overcome this problem. We summarize estimates of the relative vaccine effectiveness (rVE) of aIIV3 vs. HD-IIV3 and aIIV3 vs. standard, egg-based quadrivalent influenza vaccines (IIV4e) during the 2017–2018, 2018–2019, and 2019–2020 US influenza seasons using the same underlying electronic medical record and linked claims dataset for all three seasons. The primary outcome was influenza-related medical encounters (IRMEs), defined by diagnostic codes specific to influenza (ICD J09*-J11*). rVE was estimated using propensity score methods adjusting for demographics and health status. rVE estimates demonstrated consistent benefit for aIIV3 over IIV4e in the overall and at-risk populations. Relative to HD-IIV3, aIIV3 provided improved benefit in the overall study population and comparable benefit in the at-risk population across each season.https://www.mdpi.com/2076-393X/10/9/1456influenzainfluenza vaccinesrelative vaccine effectivenessimmunosenescence |
| spellingShingle | Constantina Boikos Ian McGovern Justin R. Ortiz Joan Puig-Barberà Eve Versage Mendel Haag Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States Vaccines influenza influenza vaccines relative vaccine effectiveness immunosenescence |
| title | Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States |
| title_full | Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States |
| title_fullStr | Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States |
| title_full_unstemmed | Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States |
| title_short | Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive Influenza Seasons in the United States |
| title_sort | relative vaccine effectiveness of adjuvanted trivalent influenza vaccine over three consecutive influenza seasons in the united states |
| topic | influenza influenza vaccines relative vaccine effectiveness immunosenescence |
| url | https://www.mdpi.com/2076-393X/10/9/1456 |
| work_keys_str_mv | AT constantinaboikos relativevaccineeffectivenessofadjuvantedtrivalentinfluenzavaccineoverthreeconsecutiveinfluenzaseasonsintheunitedstates AT ianmcgovern relativevaccineeffectivenessofadjuvantedtrivalentinfluenzavaccineoverthreeconsecutiveinfluenzaseasonsintheunitedstates AT justinrortiz relativevaccineeffectivenessofadjuvantedtrivalentinfluenzavaccineoverthreeconsecutiveinfluenzaseasonsintheunitedstates AT joanpuigbarbera relativevaccineeffectivenessofadjuvantedtrivalentinfluenzavaccineoverthreeconsecutiveinfluenzaseasonsintheunitedstates AT eveversage relativevaccineeffectivenessofadjuvantedtrivalentinfluenzavaccineoverthreeconsecutiveinfluenzaseasonsintheunitedstates AT mendelhaag relativevaccineeffectivenessofadjuvantedtrivalentinfluenzavaccineoverthreeconsecutiveinfluenzaseasonsintheunitedstates |